Sun Pharma launches anti-baldness drug Leqselvi in the US, aiming for blockbuster status after resolving patent dispute with Incyte.

• Analysts see $300–$400 million annual Leqselvi sales by FY30, with potential to reach $1 billion peak.
• Morgan Stanley notes that an aggressive patient support push signals an early market capture strategy against rivals Pfizer and Eli Lilly.
• Leqselvi could become Sun’s second-biggest product; shares rise 0.6% on potential major U.S. revenue boost.